Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Jun;32(6):848–852. doi: 10.1128/aac.32.6.848

Vancomycin pharmacokinetics in patients with various degrees of renal function.

K A Rodvold 1, R A Blum 1, J H Fischer 1, H Z Zokufa 1, J C Rotschafer 1, K B Crossley 1, L J Riff 1
PMCID: PMC172294  PMID: 3415206

Abstract

The influence of age, protein binding, and renal function on the pharmacokinetics of intravenous vancomycin was evaluated in 37 adult patients with various degrees of renal function. Patients were categorized into three groups based on measured creatinine clearance (CLCR): groups 1, 2, and 3 had 24-h CLCRs of greater than 70, 40 to 70, and 10 to 39 ml/min per 1.73 m2, respectively. After 1 h of intravenous infusion, concentrations of vancomycin in serum declined in a biexponential manner in all patients. Diminished renal function in groups 2 and 3 was accompanied by a lower total body vancomycin clearance (CL) (52.6 and 31.3, respectively, versus 98.4 ml/min per 1.73 m2) and a lower renal vancomycin clearance (CLR) (48.2 and 19.8, respectively, versus 88.0 ml/min per 1.73 m2) than in group 1. No significant differences in apparent distribution volume of the central compartment or apparent distribution volume at steady state were observed. Mean serum protein binding of vancomycin was 30% and was not significantly affected by renal function. Stepwise multiple linear regression analysis revealed that CLCR was the strongest predictor of vancomycin CL (r = 0.77, P less than 0.001) and vancomycin CLR (r = 0.87, P less than 0.001). Age did not significantly improve these correlations once CLCR was included. The relationship of vancomycin CL and CLCR was utilized to develop the following equation to dose vancomycin in the majority of renally impaired patients: dose (milligrams per kilogram per 24 h) = 0.227CLCR + 5.67, where CLCR is standardized to milliliters per minute per 70 kg. The practical dosing intervals that the calculated dose can be divided into and administered include 8, 12, 24, and 48 h based on the CLCR of the patient.

Full text

PDF
848

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blevins R. D., Halstenson C. E., Salem N. G., Matzke G. R. Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 1984 May;25(5):603–606. doi: 10.1128/aac.25.5.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Blum R. A., Rodvold K. A. Recognition and importance of Staphylococcus epidermidis infections. Clin Pharm. 1987 Jun;6(6):464–475. [PubMed] [Google Scholar]
  3. Boxenbaum H. G., Riegelman S., Elashoff R. M. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm. 1974 Apr;2(2):123–148. doi: 10.1007/BF01061504. [DOI] [PubMed] [Google Scholar]
  4. Brown N., Ho D. H., Fong K. L., Bogerd L., Maksymiuk A., Bolivar R., Fainstein V., Bodey G. P. Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother. 1983 Apr;23(4):603–609. doi: 10.1128/aac.23.4.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cheung R. P., DiPiro J. T. Vancomycin: an update. Pharmacotherapy. 1986 Jul-Aug;6(4):153–169. doi: 10.1002/j.1875-9114.1986.tb03471.x. [DOI] [PubMed] [Google Scholar]
  6. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  7. Cunha B. A., Quintiliani R., Deglin J. M., Izard M. W., Nightingale C. H. Pharmacokinetics of vancomycin in anuria. Rev Infect Dis. 1981 Nov-Dec;3 Suppl:S269–S272. [PubMed] [Google Scholar]
  8. Cutler N. R., Narang P. K., Lesko L. J., Ninos M., Power M. Vancomycin disposition: the importance of age. Clin Pharmacol Ther. 1984 Dec;36(6):803–810. doi: 10.1038/clpt.1984.260. [DOI] [PubMed] [Google Scholar]
  9. GERACI J. E., HEILMAN F. R., NICHOLS D. R., ROSS G. T., WELLMAN W. E. Some laboratory and clinical experiences with a new antibiotic, vancomycin. Proc Staff Meet Mayo Clin. 1956 Oct 17;31(21):564–582. [PubMed] [Google Scholar]
  10. Healy D. P., Polk R. E., Garson M. L., Rock D. T., Comstock T. J. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother. 1987 Mar;31(3):393–397. doi: 10.1128/aac.31.3.393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Krogstad D. J., Moellering R. C., Jr, Greenblatt D. J. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol. 1980 Apr;20(4 Pt 1):197–201. doi: 10.1002/j.1552-4604.1980.tb01696.x. [DOI] [PubMed] [Google Scholar]
  12. Lake K. D., Peterson C. D. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy. 1985 Nov-Dec;5(6):340–344. doi: 10.1002/j.1875-9114.1985.tb03441.x. [DOI] [PubMed] [Google Scholar]
  13. Lindholm D. D., Murray J. S. Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis. N Engl J Med. 1966 May 12;274(19):1047–1051. doi: 10.1056/NEJM196605122741902. [DOI] [PubMed] [Google Scholar]
  14. Magera B. E., Arroyo J. C., Rosansky S. J., Postic B. Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis. Antimicrob Agents Chemother. 1983 May;23(5):710–714. doi: 10.1128/aac.23.5.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Masur H., Francioli P., Ruddy M., Murray H. W. Vancomycin serum levels and toxicity in chronic hemodialysis patients with Staphylococcus aureus bacteremia. Clin Nephrol. 1983 Aug;20(2):85–88. [PubMed] [Google Scholar]
  16. Matzke G. R., McGory R. W., Halstenson C. E., Keane W. F. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984 Apr;25(4):433–437. doi: 10.1128/aac.25.4.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Moellering R. C., Jr, Krogstad D. J., Greenblatt D. J. Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. Rev Infect Dis. 1981 Nov-Dec;3 Suppl:S230–S235. [PubMed] [Google Scholar]
  18. Moellering R. C., Jr, Krogstad D. J., Greenblatt D. J. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med. 1981 Mar;94(3):343–346. doi: 10.7326/0003-4819-94-3-343. [DOI] [PubMed] [Google Scholar]
  19. Newfield P., Roizen M. F. Hazards of rapid administration of vancomycin. Ann Intern Med. 1979 Oct;91(4):581–581. doi: 10.7326/0003-4819-91-4-581. [DOI] [PubMed] [Google Scholar]
  20. Nielsen H. E., Hansen H. E., Korsager B., Skov P. E. Renal excretion of vancomycinin in kidney disease. Acta Med Scand. 1975 Apr;197(4):261–264. doi: 10.1111/j.0954-6820.1975.tb04914.x. [DOI] [PubMed] [Google Scholar]
  21. Nivoche Y., Contrepois A., Cremieux A. C., Carbon C. Vancomycin in rabbits: pharmacokinetics, extravascular diffusion, renal excretion and interactions with furosemide. J Pharmacol Exp Ther. 1982 Jul;222(1):237–240. [PubMed] [Google Scholar]
  22. Oellerich M., Müller-Vahl H. The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin. Clin Pharmacokinet. 1984 Jan;9 (Suppl 1):61–70. doi: 10.2165/00003088-198400091-00008. [DOI] [PubMed] [Google Scholar]
  23. Rodvold K. A., Zokufa H., Rotschafer J. C. Routine monitoring of serum vancomycin concentrations: can waiting be justified? Clin Pharm. 1987 Aug;6(8):655–658. [PubMed] [Google Scholar]
  24. Rotschafer J. C., Crossley K., Zaske D. E., Mead K., Sawchuk R. J., Solem L. D. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother. 1982 Sep;22(3):391–394. doi: 10.1128/aac.22.3.391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Schwenzer K. S., Wang C. H., Anhalt J. P. Automated fluorescence polarization immunoassay for monitoring vancomycin. Ther Drug Monit. 1983;5(3):341–345. doi: 10.1097/00007691-198309000-00017. [DOI] [PubMed] [Google Scholar]
  26. Sheagren J. N. Staphylococcus aureus. The persistent pathogen (second of two parts). N Engl J Med. 1984 May 31;310(22):1437–1442. doi: 10.1056/NEJM198405313102206. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES